Contract Manufacturing, General

The acquisition is expected to support Emergent BioSolutions’ focus on public health threats and emerging infectious disease.

The API and drug product provider will invest £375,000 (US$493,000) in additional nuclear magnetic resonance (NMR) instrumentation at its headquarters in Craigavon, UK.

This article highlights 15 years of changes in biopharmaceutical manufacturing.

TxCell announces manufacturing agreement with Lonza for its HLA-A2 CAR-Treg cellular product.

Madison Dearborn Partners will acquire a majority ownership position in CDMO Alcami.

The company has begun expansion efforts for its process-development capabilities and laboratory infrastructure.

More published data and initial regulatory approvals are needed to drive adoption of continuous bio-manufacturing.

Early adopters are benefiting from lower costs and increased productivity.

Developments and investments in single-use systems advance upstream biomanufacturing.

A review of the latest investments in facilities, equipment, and acquisitions by biopharma contract service providers.

A different perspective on controlling fixed costs of biomanufacturing, based on know-how from other industries, provides a competitive edge, says the CEO of Samsung BioLogics.

Research suggests that working with a single contract partner can reduce development time and improve economics.

Greater clarity on the application of existing regulations will accelerate development of cell and gene therapies.

The companies will be integrated to form the newly-branded AGC Biologics, which will specialize in customized contract development and manufacturing organization services for the scale-up and cGMP manufacture of protein-based therapeutics.

The contract development and manufacturing organization has invested £30-million (US$42 million) at its Dundalk, Ireland site to offer expanded clinical trial services.

The company relocated its headquarters to Riverview, Florida.

KBI Biopharma's acquisition of Elion Labs expands KBI's biophysical and analytical characterization capabilities.

Paragon Bioservices will build a new cGMP facility in Maryland and expand its existing cGMP facility at the University of Maryland's BioPark.

Abzena has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate (ADC) to clinical trials.

The European Medicines Agency has granted Samsung BioLogics approval to manufacture a monoclonal antibody at the company’s second facility in Songdo, Incheon, South Korea.

The contract research, development, and manufacturing organization has expanded API aseptic manufacturing capacity at its Valladolid, Spain, facility.

Biopharma employees reveal employment objectives, opportunities, and frustrations.

Almac Group will acquire BioClin Laboratories to expand Almac’s analytical service offerings.

ABEC, an equipment and engineering company, will provide a custom-made, single-use bioreactor to custom manufacturing firm, Emergent, for its Maryland manufacturing facility.

KBI Biopharma, a biopharmaceutical contract development and manufacturing organization, will manufacture an antibody and a fusion protein developed by Heat Biologics’ subsidiary.

ADC Bio announces plans to expand into clinical and commercial drug manufacturing for ADCs.

Contract manufacturers await a promising pipeline of drug products to jump-start stagnant growth.

The Bridgewater facility will provide a range of contract services for biopharmaceutical and pharmaceutical manufacturers, and also serve electronics chemicals suppliers.

Samsung BioLogics signs $55.5 million agreement to manufacture tildrakizumab for Sun Pharma.

The success of a truly integrated continuous processing platform relies on the collaborative efforts of upstream and downstream specialists.